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Abstract
Rationale Inhibition of glycine transporter 1 (GlyT1) ele-
vates extracellular glycine and can thus increaseN-methyl-D-
aspartate receptor (NMDAR) excitability in the brain. The
potent GlyT1 inhibitor, SSR504734, has also been shown to
potentiate the behavioral effects of direct and indirect dopa-
mine agonists. Thus, an acute systemic dose of SSR504734
was sufficient to exacerbate the motor-stimulant effect of the
dopamine releaser amphetamine in C57BL/6 mice, even
though SSR504734 alone exerted no significant effect on
motor activity.
Objectives Here, we explore if SSR504734 might modulate
dopamine-dependent sensory gating in the paradigm of
prepulse inhibition (PPI) of the acoustic startle reflex.
Methods Experiment 1 characterized the effect of
SSR504734 (10 and 30 mg/kg i.p.) on PPI expression when
administered alone. Experiments 2 and 3 investigated the
impact of SSR504734 when administered in conjunction
with the dopamine receptor agonist, apomorphine (1 and
2 mg/kg s.c.), which is known to reliably disrupt PPI.
Results When administered alone, acute SSR504734 en-
hanced PPI only at 30 mg/kg—a dose that has been shown
to improve cognitive functions including working memory,
which has been linked to enhanced NMDAR function
resulting from the elevation of extracellular glycine.
However, this effect did not allow SSR504734 to antagonize
the PPI-disruptive effect of apomorphine. At the lower dose
of 10 mg/kg—that was insufficient to enhance PPI when
administered alone—SSR504734 even exacerbated the del-
eterious effect of apomorphine on PPI.
Conclusions The therapeutic potential of GlyT1 inhibition
against distinct behavioral/cognitive deficiency might re-
quire different magnitudes of GlyT1 inhibition.
Keywords Dopamine . Glutamate . Glycine transporter 1 .
Positive symptoms . Schizophrenia . Sensorimotor gating
Introduction
There is ample evidence that hypofunction of the N-methyl-D-
aspartate receptor (NMDAR) contributes to the pathophysiol-
ogy of schizophrenia, in particular to the genesis of the neg-
ative and cognitive symptoms of the disease that cannot be
effectively treated with existing pharmacotherapy (Javitt
2010). New treatment strategies therefore aim to enhance
NMDAR activity (Javitt 2009). To date, the glycine co-
agonist site of the NMDAR complex (glycine-B site) is a
new prime target of investigation (Wallace et al. 2011).
However, despite some beneficial effects when added to con-
ventional antipsychotics (Javitt 2010), the clinical use of gly-
cine itself is limited due to poor bioavailability and brain
penetration (Wallace et al. 2011). Extracellular glycine con-
centration in glutamatergic synapses is tightly controlled by
the action of glycine transporter 1 (GlyT1), which prevents the
saturation of the glycine-B site under physiological conditions
(Berger et al. 1998; Smith et al. 1992). Inhibition of GlyT1 can
effectively enhance NMDAR-dependent signaling through
increasing synaptic glycine levels—a strategy that has been
recognized as promising in the treatment of negative and
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cognitive symptoms of schizophrenia (e.g., Javitt 2008;
Wallace et al. 2011). Several synthetic GlyT1 inhibitors have
been developed and are being evaluated clinically (Javitt
2009; Wallace et al. 2011).
Amongst the newly available GlyT1 inhibitors, we
have shown that the compound SSR504734 (2-chloro-3-
(trifluoromethyl)-N-((S)-phenyl((S)-piperidin-2-yl)methyl)
benzamide hydrochloride) reversed NMDAR antagonist-
induced hyperactivity and enhanced working memory in
C57BL/6 mice, supporting its antipsychotic and procognitive
potential (Singer et al. 2009b,c). However, SSR504734 at the
same time enhanced the motor-stimulant effect of the dopa-
mine releasing psychomimetic drug, amphetamine (Singer
et al. 2009b). This effect may be mechanistically linked to a
stimulation of the mesolimbic dopamine system, as suggested
by the finding that SSR504734 facilitates electrically evoked
dopamine release in the nucleus accumbens (NAC) (Leonetti
et al. 2006). While pro-dopaminergic interventions have been
reported to improve negative and cognitive symptoms in
medicated schizophrenia patients (e.g., Barch and Carter
2005; Kirrane et al. 2000; Sanfilipo et al. 1996), concerns
over a potential worsening of the acute psychotic (positive)
symptoms, resulting from excessive subcortical dopaminergic
activity (Carlsson 1988; Davis et al. 1991), cannot be ignored.
To further address this issue, the present study evaluated the
effect of SSR504734 on prepulse inhibition (PPI) of the
acoustic startle reflex—one of the most widely used transla-
tional paradigms in schizophrenia research (Geyer and
Moghaddam 2002). PPI is a cross-species measure of senso-
rimotor gating, defined as the attenuation of the startle
response to an intense auditory pulse stimulus, when the
stimulus is shortly preceded by a weak, nonstartling prepulse
stimulus (Graham 1975). PPI is often attenuated in schizo-
phrenia patients (e.g., Braff et al. 2001), and apomorphine-
induced PPI disruption is a well-established animal model
of the positive symptoms linked to hyperdopaminergia (for
reviews, see Geyer et al. 2001; Swerdlow et al. 2008).
Here, experiment 1 examined the effect of SSR504734
on PPI expression in normal C57BL/6 mice when ad-
ministered alone, up to a dose of 30 mg/kg intraperito-
neal (i.p.), which has been consistently shown to be
behaviorally effective (Singer et al. 2009b, c). Experiments
2 and 3 went on to test whether SSR504734 pretreatment
would interfere with the PPI-disruptive effect of acute
apomorphine.
Methods
Subjects
Subjects were naïve adult male C57BL/6NCrl mice obtained
from our in-house pathogen-free breeding colony (ETH
Zurich Laboratory of Behavioral Neurobiology, Schwerzenbach,
Switzerland). The offspring were weaned at postnatal day 21
and then kept in groups of 3–5 littermates in Makrolon®
Type-III cages (Techniplast, Milan, Italy). The animals were
maintained in a temperature (~21 °C) and humidity (~55 %)
controlled vivarium under a 12:12 h reversed light–dark
cycle (lights on at 1900 h) with ad libitum access to food
and water. Behavioral testing took place in the dark phase of
the circadian cycle, and commenced when the animals were
12 weeks old. All procedures described here were approved
by the Cantonal Veterinary Office of Zurich and conformed
to the ethical standards stipulated in the Swiss Federal Act
on Animal Protection (1978) and Swiss Animal Protection
Ordinance (1981) in accordance with the European Council
Directive 86/609/EEC (1986). All efforts had been made
to alleviate animal suffering and minimize the number of
animals used.
Drugs
All administered solutions were freshly prepared on the day
of testing. SSR504734 (gift from Sanofi-Aventis, Paris,
France) was suspended in distilled water containing 5 %
Tween 80 to obtain the appropriate concentrations to achieve
the dosages of 10 and 30 mg/kg based on an injection
volume of 10 ml/kg via the i.p. route. Apomorphine HCl
(obtained from Sigma-Aldrich, Germany) was dissolved in
1 % sterile ascorbic acid (pH 3.2) to achieve the desired
dosage of 1 or 2 mg/kg at an injection volume of 10 ml/kg
via the subcutaneous (s.c.) route. The pH was adjusted to 5.5,
with the addition of solid Na2CO3. SSR504734 and apomor-
phine (or their corresponding vehicle solutions) were admin-
istered 30 and 5 min prior to testing, respectively.
Prepulse inhibition
A full description of the apparatus and procedures is provid-
ed elsewhere (Yee et al. 2004a, b). In brief, four startle
chambers for mice (SR-LAB, San Diego Instruments, San
Diego, CA, USA) were used to measure PPI. All auditory
stimuli were in the form of white noise. A test session began
with a 2-min acclimatization period, followed by the presen-
tation of six pulse-alone trials to habituate and stabilize the
animals' startle response. The pulse stimulus was 120 dBA in
intensity and 40 ms in duration. Next, 12 blocks of discrete
test trials were presented to assess PPI. Each block consisted
of one trial of the following trial types: pulse-alone, prepulse-
alone of each of five possible prepulse intensities (69, 73, 77,
81, and 85 dBA), prepulse-plus-pulse of each of the five
levels of prepulse, and no-stimulus (i.e., background noise
alone). The 12 discrete trials within each block were
presented in a pseudorandom order, with a variable intertrial
interval averaging 15 s (ranging from 10 to 20 s). The
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duration of the prepulse stimuli was 20 ms. All trials were
presented against a constant level of background noise
(65 dBA). In prepulse-plus-pulse trials, the stimulus onset
asynchrony between the two stimuli was 100 ms. Whole
body acceleration on each trial was measured by a piezo-
electric accelerometer within a 65-ms response window
(from the onset of the pulse in pulse-alone and prepulse-
plus-pulse trials or the onset of the prepulse on prepulse-
alone trials). This output (in arbitrary units) was referred to as
reactivity score. Because the distribution of the reactivity
scores is highly positively skewed, we followed Csomor
et al.'s (2008b) recommendations to perform a logarithmic
transformation [ln (reactivity score+e) −1] prior to statistical
analysis, in order to enhance data distribution and variance
homogeneity. Pulse-alone trials and prepulse-alone trials
(including no-stimulus trials) were separately analyzed to
measure baseline startle reaction and prepulse-elicited reac-
tivity, respectively.
PPI was specifically indexed by percent inhibition (%
PPI), defined as the relative reduction in startle reaction on
prepulse-plus-pulse trials relative to pulse-alone trials and
calculated at each prepulse intensity as follows: [1−(reaction
in prepulse-plus-pulse trials)/(reaction in pulse-alone tri-
als)]×100 %. This calculation of % PPI was based on the
untransformed reactivity scores according to convention.
Statistical analyses
All data were subjected to parametric analysis of variance
(ANOVA) with the between-subject factor drug treatment
and additional within-subject factors depending on the na-
ture of the dependent variables. Statistically significant out-
comes were verified by pairwise comparisons based on ap-
propriate error variance obtained from the overall ANOVA
(Fisher's least significant difference test). Reported p values
were not adjusted for perceived inflation of familywise Type
I error rate because the post hoc comparisons were confir-
matory rather than exploratory in nature. All statistical anal-
yses were carried out using IBM SPSS statistics (version 18,
SPSS Inc. Chicago, IL, USA). A two-tailed criterion of p<
0.05 was taken as the yardstick for statistical significance.
All data illustrated in tables or figures refer to mean values±
standard error.
Results
SSR504734 enhances PPI expression at 30 mg/kg
but not at 10 mg/kg
PPI was observed in all groups, but the PPI magnitude as
indexed by % PPI was larger in the SSR 30 mg condition,
and this effect was more pronounced at high prepulse
intensities (Fig. 1). By contrast, the expression of PPI did
not substantially differ between the SSR 10 mg/kg condition
and vehicle control except at the prepulse intensity of 77 dB
(with background noise maintained at 65 dB), when % PPI
was reduced in the SSR 10 mg condition. These interpreta-
tions were supported by a 3×5 (drug×prepulse intensity)
ANOVA of % PPI, which yielded a significant effect of drug
(F(2, 35)=3.28, p<0.05) and prepulse intensity (F(4, 140)=
58.84, p<0.001) and their interaction (F(8, 140)=4.42, p<
0.001). Pairwise post hoc comparisons revealed that the
overall magnitude of % PPI significantly differed between
the SSR 10 mg and SSR 30 mg groups (p=0.02), while both
drug conditions did not significantly differ from the overall
expression of PPI in vehicle controls. Closer examination of
the two-way interaction provided clearer statistical evidence
for enhanced PPI expression in the SSR 30 mg condition
compared with controls at prepulse intensities of 81 and
88 dB (p<0.05). In addition, the comparison between SSR
10 mg and vehicle conditions at the 77 dB prepulse condition
yielded a significant difference (p<0.05). We had subsequent-
ly addressed this unique effect of SSR504734 at 10 mg/kg in
the same cohort of mice following a 2-week wash out period
and drug experience fully counterbalanced but failed to ob-
serve the same effect. Results from this supplementary exper-
iment (data not shown) confirm that SSR504734 at 10 mg/kg
exerted minimal effect on the expression of PPI.
Finally, analysis of reactivity (logarithmically transformed)
obtained on pulse-alone or prepulse-alone (including no-
stimulus trials) trials did not yield any significant group dif-
ferences (Fig. 1).
SSR504734 modulates the disruption of PPI induced
by apomorphine
We have previously shown that SSR504734 (30 mg/kg, i.p.)
enhanced the motor-depressant effect of apomorphine (0.75-
mg/kg, s.c.) in C57BL/6 mice (Singer et al. 2009b). Here,
we tested whether SSR504734 (10 or 30 mg/kg) might
similarly exacerbate the PPI disruptive effect of apomor-
phine. A relatively low dose of apomorphine (1 mg/kg)
was selected to avoid a potential floor effect that might
prevent further attenuation of PPI. As illustrated in Fig. 2,
the PPI-disruptive effect of apomorphine was relatively
weak, while combining 10 mg/kg SSR504734 with apomor-
phine produced a visibly stronger disruption than apomor-
phine alone, which was most evident at low prepulse inten-
sities. By contrast, 30 mg/kg SSR504734 did not substan-
tially modify the PPI-disruptive effect of apomorphine.
Analysis of % PPI by a 4×5 (drug×prepulse intensity)
repeated measures ANOVA yielded a significant effect of
drug (F(3, 36)=3.16, p<0.05) and prepulse intensity (F(4,
144)=77.61, p<0.001) and a significant drug×prepulse in-
tensity interaction (F(12, 144)=2.56, p<0.05). Post hoc
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comparisons indicated that PPI was significantly reduced by
10 mg/kg of SSR504734 in combination with apomorphine
relative to vehicle control (p<0.05), while the disruption
induced by apomorphine alone was weak as expected, yield-
ing only a nonsignificant trend (p=0.09). However, the over-
all expression of PPI (averaged across all prepulse intensity)
did not differ significantly between the Veh–APO and the
SSR 10 mg-APO condition (p>0.18).
The significant two-way interaction was further investi-
gated by analyzing each prepulse level using the error term
associated with the interaction effect. At a prepulse intensity
of 73 dB, combined treatment of 10 mg/kg SSR504734 and
apomorphine produced a significantly stronger decrease of
% PPI compared with apomorphine alone (p<0.05), when
apomorphine alone was also sufficient to significantly re-
duce PPI expression relative to vehicle control (p<0.05).
These results support our impression that SSR504734 at
the specific dose of 10 mg/kg exacerbated the PPI-
disruptive effect of apomorphine, and the outcomes cannot
be attributed to any confounding effects on startle reaction or
the perception of the prepulse stimulus because no drug
effect was obtained in the reactivity obtained on pulse-
alone trials or prepulse-alone trials (Fig. 2). The functional
interaction between SSR504734 and apomorphine revealed
here was further evaluated in the next experiment.
Exacerbation of the PPI-disruptive effect of apomorphine
by SSR504734 at 10 mg/kg
To further ascertain the ability of SSR504734, at 10 mg/kg,
to exacerbate the PPI-disruptive effect of apomorphine, we
performed another experiment of the same design with a
higher dose of apomorphine (2 mg/kg, s.c.) that typically
leads to a more substantial PPI disruption in C57BL/6 mice
(e.g., Russig et al. 2004; Yee et al. 2004b).
As expected, 2 mg/kg apomorphine produced a more
pronounced disruption of PPI across all prepulse intensities
relative to vehicle control (Fig. 3). Co-treatment of 10 mg/kg
SSR504734 and apomorphine led to a much stronger reduc-
tion in PPI compared with apomorphine alone. These two
effects led to the emergence of a highly significant main
effect of drug (F(2, 20)=14.08, p<0.001) in the 3×5
(drug×prepulse intensity) ANOVA of % PPI. Post hoc
pairwise comparison confirmed that all three groups substan-
tially differed from each other (Veh–Veh vs. Veh–APO: p<
0.05; Veh–Veh vs. SSR 10 mg-APO: p<0.001; Veh–APO vs.
SSR 10 mg-APO: p<0.005). As expected, the analysis also
yielded a significant effect of prepulse intensity (F(5, 100)=
11.95, p<0.001), reflecting the fact that a monotonic in-
crease of % PPI as a function of prepulse intensity was
consistently observed in all treatment groups.
Again, our finding that 10 mg/kg SSR504734 exacerbated
the PPI-disruptive effect of apomorphine was not confound-
ed by any significant treatment effects on the reaction to
pulse-alone stimuli or prepulse-alone stimuli (Fig. 3).
Discussion
The present study demonstrated that the GlyT1 inhibitor,
SSR504734, enhanced the magnitude of PPI expression at
basal level when given at a dose of 30 mg/kg, but failed to
Fig. 1 Effect of SSR504734 (10 and 30 mg/kg) on PPI. 30 mg/kg
SSR504734 (SSR) enhanced PPI as a function of increasing prepulse
intensity. 10 mg/kg SSR had little effect on PPI except at a prepulse
intensity of 77 dBA (with background noise maintained at 65 dBA),
when PPI levels were lower than in vehicle-treated animals. Asterisk
indicates significant difference at p<0.05 based on Fisher's LSD post
hoc pairwise comparisons. The table on the left shows the mean reac-
tivity obtained on pulse-alone, prepulse-alone, and no-stimulus trials (in
arbitrary units, after logarithmic transformation). “No-stimulus*” refers
to trials in which no discrete stimulus was presented except the back-
ground noise
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antagonize the PPI-disruptive effect induced by the direct
dopamine receptor agonist, apomorphine. Instead, when the
drug was administered at the lower dose of 10 mg/kg, it
exacerbated the negative impact of apomorphine on PPI.
The drug's impact on PPI expression is unlikely attributable
to any confounding effect on the generation of the whole-
body startle response or the detection of the prepulse
because neither the magnitude of the startle reaction nor
the direct reaction recorded on prepulse-alone trials was
significantly altered. Thus, SSR504734 seemingly mod-
ified sensorimotor gating underlying the interference of
prepulse perception on pulse stimulus processing in a
dose-dependent manner.
The dual effects of SSR504734 on prepulse inhibition
The enhancement of basal PPIwas only evidentwith 30mg/kg
SSR504734—the same dose has been reported to robustly
Fig. 3 SSR504734 (SSR) at 10 mg/kg exacerbated the significant
disruption of PPI induced by 2 mg/kg apomorphine (APO). 2 mg/kg
apomorphine (Veh-APO group) significantly disrupted PPI, and SSR
pretreatment at 10 mg/kg led to a more severe disruption (SSR 10 mg/
kg-APO group). Asterisk indicates significant difference at p<0.05
based on Fisher's LSD post hoc comparisons. The table on the left
shows the mean reactivity obtained on pulse-alone, prepulse-alone,
and no-stimulus trials (in arbitrary units, after logarithmic transforma-
tion). “No-stimulus*” refers to trials in which no discrete stimulus
except the background noise (65 dBA) was presented
Fig. 2 Effect of SSR504734 (10 and 30 mg/kg) on apomorphine-in-
duced PPI disruption. The co-administration of 10 mg/kg SSR504734
(SSR) with 1 mg/kg apomorphine (APO) significantly reduced PPI, while
apomorphine alone led only to a moderate nonsignificant reduction
compared with vehicle control. 30 mg/kg SSR504734 did not affect the
PPI-disruptive effect of apomorphine. Asterisk indicates significant
difference at p<0.05 based on Fisher's LSD post hoc comparisons. The
table on the left shows the mean reactivity obtained on pulse-alone,
prepulse-alone, and no-stimulus trials (in arbitrary units, after logarithmic
transformation). “No-stimulus*” refers to trials in which no discrete
stimulus except the background noise (65 dBA) was presented
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enhance working memory performance in normal C57BL/6
mice (Singer et al. 2009c). This coincidence may lead one to
suspect that these two effects share similar neural mecha-
nisms. This speculation is in line with reports of positive
correlation between PPI and working memory performance
in healthy subjects (Csomor et al. 2008a; Holstein et al. 2011;
Singer et al. 2013), indicating that individual differences in
these two tests are present in the absence of any drug manip-
ulation. Hence, even if change in PPI performance as such is
not directly responsible for specific cognitive function like
working memory, it is nonetheless an instructive behavioral
marker predictive of potential drug effect on cognitive perfor-
mance (see Geyer 2006). Our results obtained with
SSR504734 support this view.
At 10 mg/kg, PPI was, if anything, slightly reduced, albeit
non-significantly so. Closer examination showed that the
PPI-enhancing effect was the strongest at the highest
prepulse intensity. If the potentiation of PPI were simply
due to enhanced signal (prepulse) detection, it would have
been the clearest at low (rather than high) prepulse intensity,
when signal-to-noise ratio was low. The fact that the drug did
not alter the magnitude of prepulse-elicited reaction provides
further evidence against a sole effect on signal detection.
Notwithstanding, this is the first report of a PPI potentiation
by a GlyT1 inhibitor in a mouse strain other than
DBA/J2—an inbred mouse strain with characteristically
weak PPI expression (e.g., Bullock et al. 1997; Olivier
et al. 2001). Although recent attempts in outbred CF-1 and
Black Swiss mice have failed to identify a PPI-enhancing
effect of SSR504734 (Flood et al. 2011), our results show
that SSR504734's ability to enhance PPI is not unique to the
DBA/J2 genetic background (also see Singer et al. 2009a).
However, the PPI-enhancing effect by SSR504734 does not
seem to be readily generalized to other GlyT1 inhibitors. For
instance, Lipina et al. (2005) reported a dose-dependent PPI
disruption (10 and 15 mg/kg) by the compound ALX 5407
administered to C57BL/6 mice. The divergent effects on PPI
between SSR504734 and ALX 5407 might point to the
relevance of their differing mode of pharmacological action:
While ALX 5407 is a sarcosine-based noncompetitive GlyT1
inhibitor, which binds irreversibly to GlyT1, SSR504734—a
piperidinebenzamide derivative—binds reversibly to GlyT1
as a competitive inhibitor (Atkinson et al. 2001; Depoortère
et al. 2005; Mezler et al. 2008). The functional significance of
this pharmacokinetic distinction certainly warrants further
systematic investigation. Furthermore, apparently unique to
ALX5407 is its potential to act like a NMDAR antagonist at
sufficiently high doses—a property shared with another
noncompetitive GlyT1 blocker, CP-802079, which has been
shown to block NMDA-evoked currents at high doses
(Martina et al. 2004), and the resulting impairment in
NMDAR function might be responsible for the reported
PPI disruption as well as the emergence of hyperactivity
and stereotypy (Lipina et al. 2005). By contrast,
SSR504734 did not produce hyperlocomotion or stereotypy
up to 30 mg/kg (Singer et al. 2009b), and the compound
enhanced NMDA-evoked currents with increasing concen-
trations (Depoortère et al. 2005). Thus, the discrepant PPI
outcomes between GlyT1 inhibitors, at different doses and
across mouse strains, might be explicable in terms of their
associated modulatory effects on NMDAR function.
Although the exacerbation of apomorphine-induced PPI
disruption by SSR504734 was not anticipated by the drug's
effect on PPI when administered alone (at either dose), the
pattern is similar to our earlier report of SSR504734's mod-
ulation of amphetamine-induced hyperlocomotor activity
(Singer et al. 2009b). Together, our results demonstrate that
SSR504734 not only interferes with presynaptic intervention
of dopamine release (i.e., amphetamine) but also with post-
synaptic intervention that directly acts on dopamine recep-
tors (i.e., apomorphine). Mechanistically, the repeatedly ob-
served behavioral pattern may be linked to reports that
SSR504734 facilitated evoked dopamine release in the
NAC, without altering basal accumbens dopamine levels
(Depoortère et al. 2005; Leonetti et al. 2006). Since
SSR504734 does not bind to dopamine receptors
(Depoortère et al. 2005), it is unlikely that it can interfere
with postsynaptic events following dopamine receptor acti-
vation. It may be worth considering the possibility that
SSR504734 might influence upstream activities through its
indirect influence on NMDAR or even glycinergic inhibitory
signaling via strychnine-sensitive glycine receptors (GlyRs).
However, whether the interaction with the dopamine system
demonstrated here is unique to SSR504734 remains to be
ascertained because the impacts of other GlyT1 inhibiting
drugs on apomorphine-induced PPI disruption have not been
systematically evaluated. Caution against overgeneralization
is warranted here, especially when reports on amphetamine-
induced hyperactivity have yielded inconsistent outcomes
between different synthetic GlyT1 inhibitors (Boulay et al.
2008; Harsing et al. 2003).
Mechanistically, the facilitation of accumbal dopamine
release by SSR504734 is reportedly linked to enhanced
NMDAR activation, since it can be blocked by the
NMDAR antagonist AP5 (2-amino-5-phosphonopentanoic
acid) (Leonetti et al. 2006). Alternatively, GlyT1 blockade
might potentiate inhibitory signaling via GlyRs in the NAC,
which in turn leads to reduced GABAergic feedback inhibi-
tion of dopaminergic input into the NAC from the ventral
tegmental area (Lidö et al. 2009, 2011).
SSR504734 as a modulator of dopamine function
Because dopamine receptor agonist-induced hyperlo-
comotion and PPI disruption are considered as animal cor-
relates of positive schizophrenia symptoms, it is important to
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consider whether SSR504734 may worsen positive psychot-
ic symptoms in patients. The dopamine hypothesis of schizo-
phrenia emphasizes that subcortical hyperdopaminergia
coupled with prefrontal hypodopaminergia contributes to
the emergence of the positive symptoms (Carlsson 1988;
Davis et al. 1991). These hypothesized directions of dopami-
nergic dysfunction are distinct from those produced by
SSR504734: the drug increased prefrontal dopamine levels
without changing subcortical basal dopamine concentration
(Depoortère et al. 2005; Leonetti et al. 2006) and antagonized
hypersensitivity to amphetamine resulting from neonatal
chronic phencyclidine exposure in rats (Depoortère et al.
2005)—an animal model that mimics neurodevelopmental
abnormalities of schizophrenia (Wang et al. 2001). On the
other hand, SSR504734 also tended to enhance the response
to amphetamine in control rats without prior exposure to phen-
cyclidine (Depoortère et al. 2005). Thus, depending on the
differing physiological background of the subjects—perhaps,
similar to that between schizophrenia patients and acute
amphetamine abusers—SSR504734 might exert bidirectional
effects on amphetamine-induced behavior.
Given that both under and overactivity of dopamine signal-
ing have been implicated in schizophrenia, the therapeutic
potential of the stimulating action of SSR504734 on dopami-
nergic activity also deserves further consideration. Of relevance
is the finding that pro-dopaminergic stimulant drugs, including
amphetamine, have been shown to improve the negative and
cognitive symptoms in schizophrenia patients (e.g., Goldberg
et al. 1991). In healthy subjects, such drugs could enhance
working memory—an effect that has been linked to the stimu-
lation of prefrontal dopamine D1 receptors (Barch 2004; Barch
and Carter 2005; Mehta and Riedel 2006). The possibility that
such mechanisms might contribute to the reported procognitive
(Singer et al. 2009b) and antinegative symptoms effects of
SSR504734 (Black et al. 2009) has therefore been raised
(Singer et al. 2009b, c). Given that hypofunction of prefrontal
dopamine can impair PPI (Ellenbroek et al. 1996; Koch and
Bubser 1994), the enhancement in basal PPI by SSR504734 at
30 mg/kg reported here might also share similar mechanisms.
Clinical perspectives on GlyT1 inhibition
Speculation that GlyT1 inhibition may be beneficial in the
treatment of schizophrenia dates back to the late 1990s (Javitt
1997). Since then, several clinical trials have been performed
with the naturally occurring GlyT1 inhibitor, sarcosine (see the
meta-analysis by Singh and Singh 2011), which was invariably
evaluated as adjunctive treatment in combination with conven-
tional antipsychotic drugs (for reviews, see Javitt 2009; Lin
et al. 2012). The most promising GlyT1 inhibitor developed by
Hoffmann-La Roche, RG1678, which is the first-in-class com-
pound currently in phase III trial, is no exception; RG1678 is
evaluated strictly as an adjunctive treatment (Alberati et al.
2012; Umbricht et al. 2010). The effectiveness of GlyT1
inhibition as a monotherapy in patients, on the other hand, is
poorly characterized. The only available study is a small-scale
trial with sarcosine, which yielded highly ambiguous results
(Lane et al. 2008). Large-scale studies with GlyT1 inhibitors as
monotherapy are therefore urgently needed. Such studies
would facilitate comparison with preclinical studies, which
typically evaluate individual compounds in isolation (i.e.,
monotherapy) and would clarify the interaction between
GlyT1 inhibitors and (typical) antipsychotic drugs.
One favored hypothesis is that the polytherapy approach
might uniquely allow the simultaneous enhancement of corti-
cal dopaminergic activity (by GlyT1 inhibiting drugs) and
suppression of subcortical dopaminergic hyperactivity (by
dopamine D2 receptor blocking typical antipsychotics). The
combined effects might be crucial for the effective control of
positive, negative, and cognitive symptoms of schizophrenia.
Notably, a similar idea underlies the proposal of co-
administrating amphetamine with haloperidol; but chronically
exposing schizophrenia patients to amphetamine—a known
psychomimetic drug—could be a concern (e.g., Goldberg
et al. 1991). Unlike amphetamine, which is a stimulant drug
of abuse that directly facilitates the release of dopamine, the
modulation of dopamine function by SSR504734 is mediated
indirectly via its effects on NMDARs and possibly GlyRs.
Thus, the overall psychopharmacological profile of
SSR504734 does not resemble that of any psychostimulant
drug, and its use might be safer compared with amphetamine,
especially in a chronic setting. Continual efforts towards the
further characterization of the interaction between GlyT1 and
the dopaminergic system may aid future drug design (e.g.,
competitive vs. noncompetitive inhibition) and the determina-
tion of therapeutic regimes (e.g., poly vs. monotherapy) in
order to maximize efficacy in the clinics.
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